Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing

  title={Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing},
  author={Jan Grzegorzewski and Florian Bartsch and Adrian K{\"o}ller and Matthias K{\"o}nig},
  journal={Frontiers in Pharmacology},
Caffeine is by far the most ubiquitous psychostimulant worldwide found in tea, coffee, cocoa, energy drinks, and many other beverages and food. Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline. Besides its stimulating properties, two important applications of caffeine are metabolic phenotyping of cytochrome P450 1A2 (CYP1A2) and liver function testing. An open… 
1 Citations
Beyond AOPs: A Mechanistic Evaluation of NAMs in DART Testing
The mechanistic and biological coverage of existing NAMs for DART were assessed and gaps to be addressed, allowing the development of an approach that relies on generating data relevant to the overall mechanisms involved in human reproduction and embryo-foetal development.


Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
  • A. Nehlig
  • Biology, Medicine
    Pharmacological Reviews
  • 2018
A better picture is reached on how a multiplicity of biologic mechanisms seems to drive the levels of caffeine consumption, although much more knowledge is still required to understand caffeine consumption and effects on body functions.
Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat.
Caffeine pharmacokinetics may be changed by drugs affecting the activity of CYP1A2 (human and rat) or CYP2C (rat) or by treatment with certain antidepressants or neuroleptics, therefore, patients taking caffeine-containing medicine or coffee drinkers taking drugs that interact with CYP 1A2 may require proper dosage adjustments upon caffeine ingestion and cessation.
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
YP1A2 activity is the major determinant of caffeine clearance and the paraxanthine/caffeine ratios in vivo, of which the saliva ratio 6 h postdose appears as the most advantageous parameter.
HPLC determination of caffeine and paraxanthine in urine: An assay for cytochrome P450 1A2 activity
  • L. FurgeK. Fletke
  • Biology
    Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology
  • 2007
This laboratory exercise provides a means for simple assessment of P450 1A2 metabolic activity using an HPLC method without additional extraction or purification steps and introduces students to the complexities of individualized medicine as well as the basic biochemical techniques of sample preparation and quantitative HPLC.
Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2
This study illustrates two very different situations in pharmacogenetics from an almost exclusively genetic determination of NAT2 activity with no environmental modulation to only moderate genetic effects on CYP1A2Activity with strong environmental modulation.
Serum Metabolite/Caffeine Ratios as a Test for Liver Function
Metabolite/ caffeine ratios calculated in a single blood sample collected 8 or 12 hours after caffeine administration could provide a practical assessment of hepatic function in cirrhotic patients and the value of the test for the chronic hepatitis patients is limited.
Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
  • N. Hakooz
  • Biology, Medicine
    Current drug metabolism
  • 2009
Phenotyping using caffeine as a probe substrate may still provide useful assessment of CYP1A2, NAT2, XO and CYP2A6 activities in epidemiologic and drug-drug interaction studies despite the limitations that are associated with its use.
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Among caffeine-based approaches for CYP1A2, the authors recommend either plasma or saliva 17X/ 137X ratio and the urinary (AFMU + 1U + 1X + 17U + 17X)/137X ratio during a sampling interval of at least 8 hours, starting at time zero since caffeine intake.
Establishing population distribution of drug‐metabolizing enzyme activities for the use of salivary caffeine as a dynamic liver function marker in a Singaporean Chinese population
The population norm of the salivary metabolic ratio in a Singaporean Chinese population established in this study is distinct from individuals with liver disease or mild abnormal liver function tests and provides the benchmark for dosage adjustments of drugs metabolized by CYP1A2.
Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.
A pronounced variability limits the usefulness of CYP1A2 phenotyping for drug therapy, for evaluating liver function, and for assessing the role of this enzyme in carcinogenesis. To identify and